CAM2038: Ph III data

Top-line data from a double-blind, U.S. Phase III trial in 428 patients with moderate to severe opioid use disorder showed that subcutaneous CAM2038 met the FDA- and EMA-defined primary endpoints

Read the full 308 word article

User Sign In